Dental Tribune U.S. Edition No. 9, 2016

XXXXX Dental Tribune U.S. Edition | September 2016 A6 AD Crosstex acquires Accutron CantelMedicalCorp.subsidiary,Crosstex, continues its market diversification and ex- pansion with the acquisition of Accutron Inc., an industry-leading manufacturer of “conscious sedation” nitrous oxide delivery systems and nasal masks. Conscioussedationindentistryisusedto put the patient in a relaxed state during a dental procedure and is currently used in morethan50percentofalldentalpractices and more than 90 percent of pediatric den- tal practices. Conscious sedation is safe and effective, induces a relaxed state, decreases anxiety and physical movement, and may eliminate the need for local anesthesia in certain instances. This allows the practitio- ner to deliver better patient care. All Accu- tron products are FDA compliant, carry the CE Mark, are registered with Health Canada and manufactured in Accutron’s ISO 13485 facility in Phoenix, Ariz. “Conscious sedation and the safety and comfortofthepatienthavealwaysbeenthe focusofourcompany.Fromtheverybegin- ning we strived to be the market leader and market innovator in conscious sedation technology” said Accutron vice president of sales & marketing Jonathan Blasdell. “We firmly believe that by coming together as one and combining the strengths of the Crosstex marketing network, Accutron’s technology and manufacturing capabili- ties, and the continued utilization and pro- fessionalism of the PSA sales team, we can increase the understanding and expand the use of conscious sedation in dentistry.” Andrew Whitehead, senior vice president of business development, said, “Crosstex continues to diversify and expand its prod- uctportfolioandthemarketsitserves—all directly related to improving and enhanc- ing the patient experience as it relates to infection prevention, patient safety and comfort. In the past 18 months we have acquired and become the market leader in dentalunitwaterlineswiththeacquisitions of DentaPure and Liquid Ultra, entered the industrial market with the acquisition of the NAMSA sterility assurance products division, and have now entered the small- equipment/conscious sedation market with the acquisition of Accutron.” “With the strong support of our global distribution partners and our market- ing/educational focus, we will elevate the awarenessofconscioussedationasitrelates toincreasedproductionforthedentalprac- titioneraswellasimprovingthepatientex- perience in terms of infection prevention, safety and comfort,” said Gary Steinberg, president and CEO, Crosstex. “The addition of Accutron and their employees compli- ments our strategic vision. Their presence also strengthens our relationship within the dental community, both domestically and internationally, bringing increased awareness to our existing portfolio of in- fection prevention, safety and compliance products.” Crosstex manufactures a wide array of infection prevention and compliance products for the global health care indus- try. Founded in 1953 and headquartered in Hauppauge, N.Y., Crosstex is a recognized leader in products used for waterline treat- ment, biological monitoring, sterility as- surancepackagingandpersonalprotection equipment. Sold in more than 100 coun- tries, the products distributed to medical, dental and veterinary practices and facili- ties include the award-winning (five con- secutive years) Secure Fit technology face masks, DentaPure waterline treatment car- tridges and Liquid Ultra, Sure-Check ster- ilization pouches with internal/external multiparameter indicators, Tyvek pouches with 510K approval, SteamPlus Type 5 chemical integrators, ConFirm and Pass- port Plus in-office and mail-in biological indicators and Rapicide OPA/28 high level disinfectant. For more on the full line of Crosstex infection-prevention, patient-safety and compliance products, contact Crosstex at (631) 582-6777 or visit www.crosstex.com. Cantel Medical is a leading global com- pany dedicated to delivering innovative infection prevention and control products and services for patients, caregivers, and other health care providers to improve out- comes, enhance safety and help save lives. Cantel products include specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assur- ancemonitoringproductsforhospitalsand dental clinics, disposable infection control productsprimarilyfordentalandGIendos- copy markets, dialysate concentrates, hol- low fiber membrane filtration and separa- tion products, and specialty packaging for infectious and biological specimens. For more information, visit the Cantel website at www.cantelmedical.com. This article contains forward-looking statements within the meaning of the Pri- vate Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel’s fil- ings and reports with the Securities and Ex- change Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated. (Source: Crosstex) INDUSTRY NEWS

Dental Tribune U.S. Edition No. 9, 2016

Pages Overview